Clinical Trials
Numerous clinical trials evaluate doxorubicin across Early Phase 1 through Phase 3 studies for broad oncology indications, including breast cancer, leiomyosarcoma, pancreatic cancer, and hematologic malignancies. Investigating doxorubicin both as monotherapy and in combination regimens—including liposomal formulations—these studies encompass active recruiting, completed, and terminated recruitment statuses. Research is sponsored by diverse entities, ranging from academic medical centers and government organizations to pharmaceutical companies, underscoring doxorubicin's continuing role in cancer research.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07220187 | NOT_YET_RECRUITING | Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma |
SWOG Cancer Research Network |
2026-08-31 | PHASE3 |
| NCT07072585 | NOT_YET_RECRUITING | Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma; T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma |
Children's Oncology Group |
2026-08-28 | PHASE2; PHASE3 |
| NCT06947967 | RECRUITING | Lymphoma, T-Cell, Peripheral |
Chipscreen Biosciences, Ltd. |
2025-08-12 | PHASE3 |
| NCT05283720 | ACTIVE_NOT_RECRUITING | Non-Hodgkin Lymphoma |
Genmab |
2022-06-14 | PHASE2 |
| NCT07321912 | RECRUITING | Osteosarcoma; Ewing Sarcoma |
Milton S. Hershey Medical Center |
2026-06-05 | PHASE2 |
| NCT07662928 | NOT_YET_RECRUITING | Adult Burkitt Lymphoma |
AIDS Malignancy Consortium |
2026-09-17 | PHASE2 |
| NCT05605899 | ACTIVE_NOT_RECRUITING | High-risk Large B-cell Lymphoma (LBCL) |
Kite, A Gilead Company |
2023-02-10 | PHASE3 |
| NCT07517419 | ENROLLING_BY_INVITATION | Gastric Cancer Peritoneal Metastases |
Chinese University of Hong Kong |
2021-10-11 | PHASE2 |
| NCT07712588 | NOT_YET_RECRUITING | Diffuse Large B-Cell Lymphoma (DLBCL) |
Dizal Pharmaceuticals |
2026-09 | PHASE2; PHASE3 |
| NCT07551583 | RECRUITING | Hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2026-08-19 | PHASE2 |
| NCT07227584 | RECRUITING | Acute Lymphoblastic Leukemia; Philadelphia Chromosome-Negative Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia (ALL); Leukemia |
Dana-Farber Cancer Institute |
2026-04-03 | PHASE2 |
| NCT07719855 | NOT_YET_RECRUITING | Follicular Lymphoma ( FL) |
Ruijin Hospital |
2026-07 | PHASE3 |
| NCT07064018 | RECRUITING | Soft-tissue Sarcoma; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Ovarian Cancer; KRAS Mutation-Related Tumors |
University of California, Irvine |
2025-04-30 | PHASE1; PHASE2 |
| NCT05411237 | NOT_YET_RECRUITING | Kaposi Sarcoma; HIV-1-infection; AIDS-related Kaposi Sarcoma |
AIDS Malignancy Consortium |
2026-09 | PHASE3 |
| NCT06528496 | RECRUITING | High-risk Neuroblastoma; Neuroblastoma; Childhood Neuroblastoma |
Memorial Sloan Kettering Cancer Center |
2024-07-22 | PHASE2 |
| NCT06245889 | RECRUITING | Triple Negative Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2024-05-01 | PHASE2 |
| NCT06486441 | ACTIVE_NOT_RECRUITING | Endometrial Cancer |
Gilead Sciences |
2024-08-28 | PHASE3 |
| NCT05848765 | RECRUITING | Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma |
University of Birmingham |
2023-09-04 | PHASE2 |
| NCT07463313 | NOT_YET_RECRUITING | Thymoma and Thymic Carcinoma |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2026-03 | PHASE2; PHASE3 |
| NCT06829199 | WITHDRAWN | Early Triple Negative Breast Cancer |
Merck Sharp & Dohme LLC |
2025-03-26 | PHASE2 |
| NCT01419561 | RECRUITING | KSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8 |
National Cancer Institute (NCI) |
2011-09-08 | PHASE2 |
| NCT04199026 | RECRUITING | Metastatic Sarcoma; Recurrent Sarcoma; Resectable Sarcoma |
M.D. Anderson Cancer Center |
2025-02-25 | |
| NCT07218809 | RECRUITING | Epithelial Ovarian Cancer |
AstraZeneca |
2025-12-29 | PHASE3 |
| NCT03934905 | RECRUITING | Anthracycline Related Cardiotoxicity in Breast Cancer |
Texas Tech University Health Sciences Center |
2022-06-01 | PHASE1; PHASE2 |
| NCT07213804 | RECRUITING | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-10-22 | PHASE3 |
| NCT07016399 | RECRUITING | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma |
Vandana Abramson |
2025-09-09 | PHASE2 |
| NCT07224100 | RECRUITING | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1; Lymphoblastic Lymphoma |
University of Washington |
2026-03-30 | PHASE2 |
| NCT06204614 | ENROLLING_BY_INVITATION | Muscle Invasive Bladder Urothelial Carcinoma |
Brigham and Women's Hospital |
2024-06-14 | EARLY_PHASE1 |
| NCT05389423 | RECRUITING | Diffuse Large Cell Lymphoma; Non-Hodgkin Lymphoma; Burkitt Lymphoma; Plasmablastic Lymphoma; B-Cell Neoplasm |
National Cancer Institute (NCI) |
2023-06-27 | PHASE1 |
| NCT04811703 | RECRUITING | Metastatic Ovarian Carcinoma; Peritoneal Carcinomatosis; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Metastatic Malignant Neoplasm in the Peritoneum |
Hospices Civils de Lyon |
2021-07-30 | PHASE1 |
| NCT03984448 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Double-Expressor Lymphoma; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma |
National Cancer Institute (NCI) |
2019-10-22 | PHASE2; PHASE3 |
| NCT07486310 | NOT_YET_RECRUITING | Advanced Gastric Cancer |
Guangdong Provincial People's Hospital |
2026-03-01 | PHASE2 |
| NCT06091254 | RECRUITING | Follicular Lymphoma (FL) |
Regeneron Pharmaceuticals |
2023-12-12 | PHASE3 |
| NCT07676175 | NOT_YET_RECRUITING | Previously Untreated Peripheral T-Cell Lymphoma |
BeBetter Med Inc |
2026-07-01 | PHASE2 |
| NCT07049848 | RECRUITING | Soft Tissue Sarcoma |
M.D. Anderson Cancer Center |
2025-09-11 | PHASE2 |
| NCT03719105 | RECRUITING | NK-Cell Lymphoma; NK-Cell Leukemia; Peripheral T Cell Lymphoma |
New York Medical College |
2019-03-01 | EARLY_PHASE1 |
| NCT06849986 | RECRUITING | Soft Tissue Sarcomas; Angiosarcoma; Fibrosarcoma; Leiomyosarcoma; Pleomorphic Liposarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Desmoplastic Small Round Cell Tumor |
Fudan University |
2025-02-25 | PHASE2 |
| NCT05610735 | RECRUITING | Recurrent Ovarian Cancer |
Sham Sunder Kakar |
2024-09-25 | PHASE1; PHASE2 |
| NCT06297512 | RECRUITING | Glioblastoma |
Iacopo Sardi |
2022-12-09 | PHASE2 |
| NCT05404945 | ACTIVE_NOT_RECRUITING | Classical Hodgkin Lymphoma |
University of Virginia |
2022-07-26 | PHASE2 |
| NCT06318897 | RECRUITING | Stage 1 cT1b-T1cN0M0; Triple Negative Breast Cancer |
M.D. Anderson Cancer Center |
2024-05-29 | PHASE2 |
| NCT03914625 | ACTIVE_NOT_RECRUITING | B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome |
National Cancer Institute (NCI) |
2019-07-03 | PHASE3 |
| NCT05949021 | ACTIVE_NOT_RECRUITING | Triple Negative Breast Cancer (TNBC) |
Mridula George, MD |
2023-10-07 | PHASE2 |
| NCT05020860 | RECRUITING | Breast Cancer; Breast Neoplasm; Breast Cancer Female; Breast Cancer Invasive; Breast Cancer Stage II; Breast Cancer Stage III; Triple Negative Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Triple Negative Breast Neoplasms; Estrogen Receptor-positive Breast Cancer |
Baylor Breast Care Center |
2023-04-18 | PHASE2 |
| NCT06815575 | RECRUITING | Solid Tumours; Advanced Solid Tumours |
Racura Oncology Ltd |
2025-04-02 | PHASE1 |
| NCT06312176 | RECRUITING | Breast Neoplasms |
Merck Sharp & Dohme LLC |
2024-04-14 | PHASE3 |
| NCT05279300 | SUSPENDED | Advanced Solid Tumor; Advanced Lymphoma |
CStone Pharmaceuticals |
2022-03-28 | PHASE1 |
| NCT04301076 | RECRUITING | Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; Chronic Adult T-Cell Leukemia/Lymphoma; HTLV-1 Infection |
National Cancer Institute (NCI) |
2021-08-31 | PHASE1 |
| NCT06994195 | RECRUITING | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2025-08-04 | PHASE3 |
| NCT04803201 | RECRUITING | Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Follicular T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Peripheral T-Cell Lymphoma, Not Otherwise Specified |
Alliance for Clinical Trials in Oncology |
2021-10-08 | PHASE2 |
| NCT07081022 | ACTIVE_NOT_RECRUITING | B-cell Non-Hodgkin's Lymphoma |
Shanghai Junshi Bioscience Co., Ltd. |
2025-08-17 | PHASE2 |
| NCT01840592 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
Memorial Sloan Kettering Cancer Center |
2013-04 | PHASE2 |
| NCT05377905 | RECRUITING | Cutaneous Squamous Cell Carcinoma; Skin Cancers - Squamous Cell Carcinoma |
Falo, Louis, MD |
2023-09-13 | PHASE1; PHASE2 |
| NCT03710772 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma |
M.D. Anderson Cancer Center |
2019-05-01 | PHASE2 |
| NCT04978584 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma |
M.D. Anderson Cancer Center |
2022-03-03 | PHASE2 |
| NCT01970722 | ACTIVE_NOT_RECRUITING | FIGO Stage IVA Ovarian Cancer; FIGO Stage IVB Ovarian Cancer; Platinum-Resistant Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Fallopian Tube Cancer AJCC v7; Stage III Ovarian Cancer AJCC v6 and v7; Stage III Primary Peritoneal Cancer AJCC v7; Stage III Uterine Corpus Cancer AJCC v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IIIC Uterine Corpus Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7 |
City of Hope Medical Center |
2014-05-19 | PHASE1 |
| NCT03937830 | ACTIVE_NOT_RECRUITING | Hepatocellular Cancer; Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma |
National Cancer Institute (NCI) |
2021-03-10 | PHASE2 |
| NCT04638790 | RECRUITING | Hodgkin Lymphoma, Adult |
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia |
2020-02-01 | PHASE3 |
| NCT07635342 | RECRUITING | HER2-positive Breast Cancer |
Hebei Medical University Fourth Hospital |
2024-04-30 | PHASE2 |
| NCT06526923 | RECRUITING | Cystic Fibrosis |
Spirovant Sciences, Inc. |
2024-09-16 | PHASE1; PHASE2 |
| NCT06751485 | NOT_YET_RECRUITING | Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
2025-01-15 | PHASE3 |
| NCT03805022 | RECRUITING | Non-metastatic Soft-tissue Sarcoma; Resectable |
Institut Bergonié |
2019-02-14 | PHASE3 |
| NCT01025089 | ACTIVE_NOT_RECRUITING | Thymoma; Thymic Carcinoma; Clinical Masaoka Stage II to IVA |
Memorial Sloan Kettering Cancer Center |
2009-12 | PHASE2 |
| NCT05281471 | RECRUITING | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma |
Genelux Corporation |
2022-08-31 | PHASE3 |
| NCT02877303 | RECRUITING | B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma |
M.D. Anderson Cancer Center |
2016-11-01 | PHASE2 |
| NCT00501826 | RECRUITING | T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma |
M.D. Anderson Cancer Center |
2007-07-11 | PHASE2 |
| NCT06977711 | RECRUITING | Diffuse Large B-cell Lymphoma |
The University of Texas Health Science Center at San Antonio |
2025-06-20 | PHASE1 |
| NCT06210750 | WITHDRAWN | T Acute Lymphoblastic Leukemia; T Lymphoblastic Lymphoma |
National Cancer Institute (NCI) |
2024-08-09 | PHASE2 |
| NCT04776525 | RECRUITING | Soft Tissue Sarcoma |
Oslo University Hospital |
2021-04-27 | PHASE2 |
| NCT05498896 | ACTIVE_NOT_RECRUITING | Triple Negative Breast Cancer |
Queen Mary University of London |
2018-12-19 | PHASE2 |
| NCT07349459 | NOT_YET_RECRUITING | Melatonin; Breast Cancer Patients Diagnosed; Vitamin D Concentration; Doxorubicin |
Tanta University |
2026-04-30 | |
| NCT05457829 | RECRUITING | Rhabdomyosarcoma, Child |
Sun Yat-sen University |
2023-12-30 | PHASE2 |
| NCT04850495 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma |
Yazeed Sawalha |
2021-11-16 | PHASE1 |
| NCT05351346 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2022-06-01 | PHASE3 |
| NCT05630209 | ACTIVE_NOT_RECRUITING | Brain Tumor |
InSightec |
2023-01-04 | PHASE1; PHASE2 |
| NCT06701344 | NOT_YET_RECRUITING | Enteropathy Associated T Cell Lymphoma |
Ruijin Hospital |
2024-12-04 | PHASE2 |
| NCT05934097 | WITHDRAWN | Diffuse Large B Cell Lymphoma; Transformed Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma |
Fate Therapeutics |
2022-12 | PHASE1 |
| NCT05453500 | ACTIVE_NOT_RECRUITING | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative |
University of Washington |
2023-03-27 | PHASE2 |
| NCT02723994 | COMPLETED | Leukemia |
Incyte Corporation |
2016-09-30 | PHASE2 |
| NCT04872985 | ACTIVE_NOT_RECRUITING | Breast Cancer; Hormone-receptor Positive Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-04-20 | PHASE2 |
| NCT04092270 | ACTIVE_NOT_RECRUITING | Endometrial High Grade Endometrioid Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor; Recurrent Ovarian Mucinous Adenocarcinoma; Recurrent Ovarian Transitional Cell Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma |
National Cancer Institute (NCI) |
2020-05-07 | PHASE1 |
| NCT04650984 | UNKNOWN | Soft Tissue Sarcoma |
Philogen S.p.A. |
2017-11-29 | PHASE3 |
| NCT03269669 | ACTIVE_NOT_RECRUITING | Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma |
National Cancer Institute (NCI) |
2018-01-23 | PHASE2 |
| NCT03719430 | COMPLETED | Soft Tissue Sarcoma |
Alexander Z. Wei, MD |
2019-03-20 | PHASE2 |
| NCT02710734 | COMPLETED | Urothelial Carcinoma of the Bladder |
Fox Chase Cancer Center |
2016-02-24 | PHASE2 |
| NCT05824975 | RECRUITING | Advanced Solid Tumor; Metastatic Solid Tumor; Soft Tissue Sarcoma (STS); Platinum-resistant Ovarian Cancer (PROC); Hepatocellular Carcinoma (HCC); Colorectal Cancer (CRC); HER2 Negative Breast Cancer; Cutaneous Melanoma; Renal Cell Carcinoma (RCC) |
GI Innovation, Inc. |
2023-05-30 | PHASE1; PHASE2 |
| NCT06404463 | NOT_YET_RECRUITING | Early Breast Cancer; Neoadjuvant Therapy; HR+HER2- Breast Cancer |
Fudan University |
2024-05-06 | PHASE2 |
| NCT03036488 | COMPLETED | Triple Negative Breast Neoplasms |
Merck Sharp & Dohme LLC |
2017-03-07 | PHASE3 |
| NCT04835870 | UNKNOWN | Non-GCB/ABC Diffuse Large B-Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2021-04-01 | PHASE2 |
| NCT03340376 | UNKNOWN | Cervical Cancer |
Universitaire Ziekenhuizen KU Leuven |
2017-08-30 | PHASE2 |
| NCT05422066 | UNKNOWN | DLBCL Germinal Center B-Cell Type |
Li Zhiming |
2022-07-26 | PHASE2 |
| NCT03233347 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage I Hodgkin Lymphoma; Ann Arbor Stage IA Hodgkin Lymphoma; Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Classic Hodgkin Lymphoma |
Academic and Community Cancer Research United |
2017-10-13 | PHASE2 |
| NCT04757337 | UNKNOWN | Advanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma |
UNICANCER |
2021-06-18 | PHASE3 |
| NCT05051891 | COMPLETED | Treatment-naїve Mantle Cell Lymphoma |
Beijing InnoCare Pharma Tech Co., Ltd. |
2021-12-22 | PHASE3 |
| NCT03983226 | RECRUITING | Ovarian Cancer Recurrent; Fallopian Tube Cancer; Primary Peritoneal Carcinoma |
Shanghai Gynecologic Oncology Group |
2019-10-18 | PHASE2 |
| NCT06703593 | COMPLETED | Breast Cancer Female |
British University In Egypt |
2023-10-01 | PHASE2 |
| NCT05201248 | ACTIVE_NOT_RECRUITING | B-Cell Non-Hodgkin Lymphoma |
Genmab |
2022-03-10 | PHASE1; PHASE2 |
| NCT05238064 | UNKNOWN | PI3Kδ Inhibitor; Parsaclisib; CHOP; PTCL |
Fudan University |
2022-03 | PHASE1; PHASE2 |
| NCT02853500 | WITHDRAWN | Liver Cancer |
Dana-Farber Cancer Institute |
2016-07 | PHASE4 |
| NCT07171827 | COMPLETED | Anti-CD30; Brentuximab; Doxorubicin; Vinblastine; Dacarbazine; Frontline; Advanced Classical Hodgkin Lymphoma |
Helwan University |
2023-03-01 | |
| NCT04679064 | UNKNOWN | Ovarian Cancer |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2020-12-01 | PHASE3 |
| NCT04432714 | RECRUITING | DLBCL; Untreated; MYC Gene Rearrangement |
The First Affiliated Hospital with Nanjing Medical University |
2020-06-09 | PHASE1; PHASE2 |
| NCT07668076 | COMPLETED | Breast Cancer; Doxorubicin Induced Cardiomyopathy |
Damanhour University |
2022-11-15 | PHASE2 |
| NCT03220022 | ACTIVE_NOT_RECRUITING | AIDS-Related Lymphoma; Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma |
National Cancer Institute (NCI) |
2018-03-16 | PHASE1 |
| NCT02584478 | UNKNOWN | Endometrial Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Cervical Carcinoma |
Advenchen Laboratories, LLC |
2015-12 | PHASE3 |
| NCT05747521 | UNKNOWN | Soft Tissue Sarcoma |
Henan Cancer Hospital |
2021-04-29 | |
| NCT04980222 | ACTIVE_NOT_RECRUITING | Lymphoma |
Hoffmann-La Roche |
2022-03-22 | PHASE2 |
| NCT03598270 | COMPLETED | Recurrent Ovarian Carcinoma |
Grupo Español de Investigación en Cáncer de Ovario |
2018-11-21 | PHASE3 |
| NCT00878254 | COMPLETED | Mantle-Cell Lymphoma |
University of Miami |
2009-03-25 | PHASE2 |
| NCT05613088 | COMPLETED | Neoplasms, Ovarian |
Bristol-Myers Squibb |
2023-02-01 | PHASE2 |
| NCT04383743 | COMPLETED | Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Muscle Invasive Bladder Carcinoma |
University of Washington |
2020-11-24 | PHASE2 |
| NCT04656262 | TERMINATED | Soft Tissue Sarcoma Adult |
Istituto Oncologico Veneto IRCCS |
2018-09-10 | PHASE3 |
| NCT05872412 | UNKNOWN | Triple Negative Breast Cancer |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2023-06-01 | PHASE2 |
| NCT03794778 | UNKNOWN | Efficacy and Safety |
Women's Hospital School Of Medicine Zhejiang University |
2019-03-19 | PHASE4 |
| NCT03505762 | ACTIVE_NOT_RECRUITING | B-Cell Non-Hodgkin Lymphoma |
Wake Forest University Health Sciences |
2018-07-19 | PHASE2 |
| NCT03793361 | COMPLETED | Metastatic Soft Tissue Sarcoma |
Centre Oscar Lambret |
2019-05-15 | PHASE2 |
| NCT04974996 | WITHDRAWN | Diffuse Large B-Cell Lymphoma |
ADC Therapeutics S.A. |
2022-02-01 | PHASE1 |
| NCT04213794 | TERMINATED | Malignant Abdominal Neoplasm; Malignant Pelvic Neoplasm; Recurrent Colon Carcinoma; Recurrent Desmoplastic Small Round Cell Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Gastric Carcinoma; Recurrent Liposarcoma; Recurrent Malignant Mesothelioma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Rectal Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Sarcoma; Refractory Colon Carcinoma; Refractory Desmoplastic Small Round Cell Tumor; Refractory Fallopian Tube Carcinoma; Refractory Gastric Carcinoma; Refractory Liposarcoma; Refractory Malignant Mesothelioma; Refractory Ovarian Carcinoma; Refractory Primary Peritoneal Carcinoma; Refractory Rectal Carcinoma; Refractory Rhabdomyosarcoma; Refractory Sarcoma; Resectable Liposarcoma; Resectable Malignant Mesothelioma; Resectable Sarcoma |
Mayo Clinic |
2019-11-08 | EARLY_PHASE1 |
| NCT00390793 | COMPLETED | Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; t(9;22) |
M.D. Anderson Cancer Center |
2006-09-28 | PHASE2 |
| NCT04922567 | RECRUITING | Peripheral T-Cell Lymphoma; Lenalidomide; CHOP |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2021-04-01 | PHASE2 |
| NCT04928222 | ACTIVE_NOT_RECRUITING | Basal Cell Carcinoma |
SkinJect, Inc. |
2021-09-24 | PHASE1; PHASE2 |
| NCT00657878 | UNKNOWN | Ovarian Cancer |
National Cancer Institute, Naples |
2008-11 | PHASE3 |
| NCT06186700 | Active not recruiting | Breast Cancer Female |
Mansoura University |
2023-12-25 | Phase 2 |
| NCT05567601 | Not yet recruiting | Ovarian Cancer|AIDS-related Kaposi Sarcoma|Multiple Myeloma|Metastatic Breast Cancer |
Baxter Healthcare Corporation |
2023-11-30 | Phase 1 |
| NCT04172259 | ACTIVE_NOT_RECRUITING | Breast Cancer; Neoadjuvant Chemotherapy |
Sun Yat-sen University |
2019-01-10 | PHASE2 |
| NCT02626455 | TERMINATED | Lymphoma, Non-Hodgkin |
Bayer |
2016-01-06 | PHASE3 |
| NCT06088290 | Recruiting | Leiomyosarcoma |
PharmaMar |
2023-09-21 | Phase 2|Phase 3 |
| NCT04038489 | WITHDRAWN | Breast Cancer; Estrogen Receptor-positive Breast Cancer |
University of Virginia |
2019-10-18 | PHASE2 |
| NCT02312245 | COMPLETED | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
Mayo Clinic |
2015-07-21 | PHASE2 |
| NCT04480099 | UNKNOWN | Peripheral T-cell Lymphoma |
Ruijin Hospital |
2020-07-29 | PHASE2 |
| NCT04925089 | Recruiting | Leiomyosarcoma |
University of Michigan Rogel Cancer Center|National Cancer Institute (NCI) |
2023-04-26 | -- |
| NCT04852367 | WITHDRAWN | Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV; Pancreatic Cancer Non-resectable; Pancreatic Cancer Metastatic |
University of Oxford |
2021-06-16 | PHASE1 |
| NCT02372409 | TERMINATED | Glioma; Pilocytic Astrocytoma; Anaplastic Astrocytoma; Glioblastoma; Mixed Oligoastrocytoma; Mixed Glioma; Oligodendroglioma; Optic Glioma; Astrocytoma |
Washington University School of Medicine |
2015-08-14 | PHASE2 |
| NCT00003927 | COMPLETED | Breast Cancer |
City of Hope Medical Center |
1999-05-18 | PHASE1 |
| NCT04584112 | COMPLETED | Triple-Negative Breast Cancer |
Hoffmann-La Roche |
2020-09-28 | PHASE1 |
| NCT04209855 | COMPLETED | Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer |
AbbVie |
2019-12-31 | PHASE3 |
| NCT04842318 | UNKNOWN | Follicular Lymphoma |
Ruijin Hospital |
2021-03-01 | PHASE4 |
| NCT04753177 | UNKNOWN | The Neoadjuvant Therapy |
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary |
2021-01-28 | PHASE2; PHASE3 |
| NCT04739800 | ACTIVE_NOT_RECRUITING | Fallopian Tube Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Ovarian Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Mucinous Adenocarcinoma; Recurrent Fallopian Tube Transitional Cell Carcinoma; Recurrent Fallopian Tube Undifferentiated Carcinoma; Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Ovarian Low Grade Serous Adenocarcinoma; Recurrent Ovarian Mucinous Adenocarcinoma; Recurrent Ovarian Seromucinous Carcinoma; Recurrent Ovarian Transitional Cell Carcinoma; Recurrent Ovarian Undifferentiated Carcinoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Clear Cell Adenocarcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Transitional Cell Carcinoma; Recurrent Primary Peritoneal Undifferentiated Carcinoma; Refractory Fallopian Tube Clear Cell Adenocarcinoma; Refractory Fallopian Tube Endometrioid Adenocarcinoma; Refractory Fallopian Tube High Grade Serous Adenocarcinoma; Refractory Fallopian Tube Mucinous Adenocarcinoma; Refractory Fallopian Tube Transitional Cell Carcinoma; Refractory Fallopian Tube Undifferentiated Carcinoma; Refractory Low Grade Fallopian Tube Serous Adenocarcinoma; Refractory Ovarian Clear Cell Adenocarcinoma; Refractory Ovarian Endometrioid Adenocarcinoma; Refractory Ovarian High Grade Serous Adenocarcinoma; Refractory Ovarian Low Grade Serous Adenocarcinoma; Refractory Ovarian Mucinous Adenocarcinoma; Refractory Ovarian Seromucinous Carcinoma; Refractory Ovarian Transitional Cell Carcinoma; Refractory Ovarian Undifferentiated Carcinoma; Refractory Primary Peritoneal Clear Cell Adenocarcinoma; Refractory Primary Peritoneal Endometrioid Adenocarcinoma; Refractory Primary Peritoneal High Grade Serous Adenocarcinoma; Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma; Refractory Primary Peritoneal Transitional Cell Carcinoma; Refractory Primary Peritoneal Undifferentiated Carcinoma |
National Cancer Institute (NCI) |
2021-06-10 | PHASE2 |
| NCT01990352 | TERMINATED | Breast Cancer |
University of Arizona |
2013-11-05 | PHASE2 |
| NCT03071926 | UNKNOWN | Advanced Breast Cancer |
Fudan University |
2017-03-01 | PHASE2 |
| NCT02661503 | UNKNOWN | Classical Hodgkin Lymphoma |
University of Cologne |
2016-07 | PHASE3 |
| NCT03749850 | UNKNOWN | Metastatic Breast Cancer; Breast Cancer; Breast Neoplasms; Stage IV Breast Cancer; Metastatic Cancer; Invasive Ductal Carcinoma of Female Breast; Invasive Ductal Breast Cancer; Adenocarcinoma Breast |
UMC Utrecht |
2021-03 | PHASE1 |
| NCT02636322 | COMPLETED | Diffuse Large B-Cell Lymphoma Unclassifiable |
M.D. Anderson Cancer Center |
2016-03-29 | PHASE2 |
| NCT04358341 | UNKNOWN | Gastric Cancer |
Sixth Affiliated Hospital, Sun Yat-sen University |
2020-06-17 | PHASE2 |
| NCT03808480 | UNKNOWN | Non-small Cell Lung Cancer |
National Cancer Center, Korea |
2019-01-23 | PHASE2 |
| NCT01974440 | COMPLETED | Lymphoma |
Janssen Research & Development, LLC |
2014-01-31 | PHASE3 |
| NCT04081389 | COMPLETED | Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Early-Stage Breast Carcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma |
Roswell Park Cancer Institute |
2019-12-06 | PHASE1 |
| NCT04660799 | COMPLETED | Lymphoma, Large B-Cell, Diffuse |
Hoffmann-La Roche |
2021-02-24 | PHASE2 |
| NCT03539328 | UNKNOWN | Ovarian Cancer |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2018-06 | PHASE2 |
| NCT04356872 | UNKNOWN | Sarcoma, Soft Tissue |
Fudan University |
2020-04-08 | PHASE2 |
| NCT03517449 | COMPLETED | Endometrial Neoplasms |
Eisai Inc. |
2018-06-11 | PHASE3 |
| NCT03792867 | UNKNOWN | Retroperitoneal Sarcoma |
National Cancer Centre, Singapore |
2018-07-23 | |
| NCT02166463 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Childhood Hodgkin Lymphoma; Classic Hodgkin Lymphoma |
National Cancer Institute (NCI) |
2015-03-19 | PHASE3 |
| NCT04024462 | COMPLETED | HER2-positive Early Breast Cancer |
Hoffmann-La Roche |
2020-02-05 | PHASE3 |
| NCT03335241 | UNKNOWN | Ovarian Cancer |
Sun Yat-sen University |
2017-03-01 | PHASE2 |
| NCT01882816 | COMPLETED | Thyroid Cancer |
Memorial Sloan Kettering Cancer Center |
2013-06-13 | PHASE2 |
| NCT02577783 | UNKNOWN | Multiple Myeloma |
The First Affiliated Hospital of Soochow University |
2015-10 | PHASE4 |
| NCT01779050 | TERMINATED | Breast Neoplasms |
Washington University School of Medicine |
2013-12-19 | PHASE2 |
| NCT02918747 | UNKNOWN | Lymphoma |
Hunan Cancer Hospital |
2016-09 | PHASE2 |
| NCT02766699 | COMPLETED | Glioblastoma; Astrocytoma, Grade IV |
Engeneic Pty Limited |
2016-10-25 | PHASE1 |
| NCT02822157 | UNKNOWN | Ovarian Epithelial Cancer |
Universitaire Ziekenhuizen KU Leuven |
2016-08 | PHASE2 |
| NCT03591276 | RECRUITING | Metastatic Breast Cancer |
Shaare Zedek Medical Center |
2019-04-18 | PHASE1; PHASE2 |
| NCT03596281 | COMPLETED | Ovarian Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2018-12-05 | PHASE1 |
| NCT04231929 | WITHDRAWN | Hepatocellular Carcinoma |
Terumo Europe N.V. |
2020-05 | |
| NCT01004978 | COMPLETED | Hepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma |
National Cancer Institute (NCI) |
2009-10-28 | PHASE3 |
| NCT03892330 | NOT_YET_RECRUITING | 0.5-14 Year Old Children With Nephroblastoma |
Shengjing Hospital |
2019-06-01 | PHASE4 |
| NCT03603379 | COMPLETED | Glioblastoma |
University Hospital, Basel, Switzerland |
2018-11-16 | PHASE1 |
| NCT03452553 | WITHDRAWN | Hepatocellular Carcinoma (HCC) |
Boston Scientific Corporation |
2018-07-01 | |
| NCT03908528 | COMPLETED | Breast Cancer; Chemotherapeutic Toxicity |
Damanhour University |
2019-03-01 | |
| NCT03617432 | UNKNOWN | Experimental Tumor |
Peking University |
2018-08-28 | PHASE2 |
| NCT03294577 | UNKNOWN | Chemotherapy-induced Neutropenia |
BeyondSpring Pharmaceuticals Inc. |
2019-10-23 | PHASE3 |
| NCT03002805 | UNKNOWN | Sarcoma |
CBA Research |
2018-03-29 | PHASE1 |
| NCT02506777 | UNKNOWN | Breast Cancer |
N.N. Petrov National Medical Research Center of Oncology |
2015-07 | PHASE2 |
| NCT02790580 | UNKNOWN | Breast Cancer |
National University Hospital, Singapore |
2016-05 | PHASE2 |
| NCT03276013 | COMPLETED | Endometrial Neoplasms |
Vall d'Hebron Institute of Oncology |
2018-05-30 | PHASE2 |
| NCT01363128 | COMPLETED | Acute Lymphoblastic Leukemia; Adult Acute Lymphoblastic Leukemia in Complete Remission; Burkitt Leukemia; Burkitt Lymphoma; CD20 Positive; Childhood Acute Lymphoblastic Leukemia in Complete Remission; Lymphoblastic Lymphoma |
M.D. Anderson Cancer Center |
2011-07-12 | PHASE2 |
| NCT02758366 | TERMINATED | Glioblastoma (GBM); DIPG; Brainstem Glioma, Pediatric; Diffuse Spinal Glioma; Bilateral Thalamic Glioma; Gliomatosis Cerebri; Anaplastic Astrocytoma; Midline Diffuse Glioma |
Meyer Children's Hospital IRCCS |
2016-02 | PHASE2 |
| NCT02978495 | COMPLETED | BRCA1 Hereditary Breast and Ovarian Cancer Syndrome |
Barretos Cancer Hospital |
2017-05-17 | PHASE2 |
| NCT02858804 | COMPLETED | Mantle Cell Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2016-01 | PHASE4 |
| NCT00058422 | COMPLETED | Lymphoma |
Memorial Sloan Kettering Cancer Center |
2003-02-10 | PHASE2 |
| NCT03949634 | UNKNOWN | Early Breast Cancer |
Fudan University |
2017-09-01 | PHASE3 |
| NCT03009201 | COMPLETED | Advanced Soft Tissue Sarcoma; Locally Advanced Angiosarcoma; Locally Advanced Leiomyosarcoma; Locally Advanced Liposarcoma; Locally Advanced Malignant Peripheral Nerve Sheath Tumor; Locally Advanced Myxofibrosarcoma; Locally Advanced Undifferentiated Pleomorphic Sarcoma; Metastatic Angiosarcoma; Metastatic Epithelioid Sarcoma; Metastatic Fibrosarcoma; Metastatic Liposarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Myxofibrosarcoma; Metastatic Soft Tissue Sarcoma; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma; Pleomorphic Rhabdomyosarcoma; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Undifferentiated (Embryonal) Sarcoma; Unresectable Leiomyosarcoma; Unresectable Liposarcoma; Unresectable Malignant Peripheral Nerve Sheath Tumor; Unresectable Soft Tissue Sarcoma; Unresectable Synovial Sarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma |
OHSU Knight Cancer Institute |
2017-03-10 | PHASE1 |
| NCT02449278 | UNKNOWN | Diffuse Large B-cell Lymphoma |
Wuhan University |
2015-10 | PHASE3 |
| NCT02751918 | COMPLETED | Ovarian Neoplasms |
Bayer |
2016-06-08 | PHASE1 |
| NCT03493854 | COMPLETED | Early Breast Cancer |
Hoffmann-La Roche |
2018-06-14 | PHASE3 |
| NCT02180867 | COMPLETED | Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Fibrosarcoma; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Liver Embryonal Sarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Peripheral Nerve Sheath Tumor; Malignant Skin Granular Cell Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Skin Glomus Tumor; Stage IB Soft Tissue Sarcoma AJCC v7; Stage IIB Soft Tissue Sarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Synovial Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone |
National Cancer Institute (NCI) |
2014-08-12 | PHASE2; PHASE3 |
| NCT01889069 | COMPLETED | Lymphoma |
Hoffmann-La Roche |
2013-07-31 | PHASE3 |
| NCT02951728 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2016-10 | PHASE1; PHASE2 |
| NCT01670500 | COMPLETED | Breast Cancer |
Beth Israel Deaconess Medical Center |
2012-10 | PHASE2 |
| NCT03283696 | COMPLETED | Soft Tissue Sarcoma |
Eli Lilly and Company |
2017-10-18 | PHASE1 |
| NCT02631876 | COMPLETED | Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer |
ImmunoGen, Inc. |
2016-03-02 | PHASE3 |
| NCT01992653 | COMPLETED | Lymphoma, Non Hodgkin |
Genentech, Inc. |
2013-11-29 | PHASE1; PHASE2 |
| NCT02451943 | COMPLETED | Soft Tissue Sarcoma |
Eli Lilly and Company |
2015-09-14 | PHASE3 |
| NCT02562378 | COMPLETED | Breast Cancer |
MedSIR |
2015-10 | PHASE1 |
| NCT02994251 | TERMINATED | Unresectable Intrahepatic Cholangiocarcinoma |
Yale University |
2017-06-21 | PHASE2 |
| NCT02421588 | COMPLETED | Ovarian Cancer |
PharmaMar |
2015-05 | PHASE3 |
| NCT02548780 | COMPLETED | HCC; Hepatocellular Carcinoma |
Terumo Europe N.V. |
2016-04 | |
| NCT02412670 | COMPLETED | High Grade Upper Tract Urothelial Carcinoma |
ECOG-ACRIN Cancer Research Group |
2015-08-27 | PHASE2 |
| NCT00278421 | COMPLETED | Lymphoma |
German High-Grade Non-Hodgkin's Lymphoma Study Group |
2005-11 | PHASE3 |
| NCT03188198 | UNKNOWN | Large B Cell Lymphoma |
Mansoura University |
2016-06-01 | PHASE2 |
| NCT02622074 | COMPLETED | Triple Negative Breast Neoplasms |
Merck Sharp & Dohme LLC |
2016-01-27 | PHASE1 |
| NCT03425656 | COMPLETED | Malignant Neoplasm of Breast |
AryoGen Pharmed Co. |
2016-07-09 | PHASE3 |
| NCT01156883 | COMPLETED | Leukemia |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2010-04 | |
| NCT02494713 | TERMINATED | Prostate Cancer |
The University of Texas Health Science Center, Houston |
2015-10 | PHASE2 |
| NCT02560051 | TERMINATED | Prostatic Neoplasms |
The University of Texas Health Science Center, Houston |
2015-11 | PHASE2 |
| NCT00801281 | COMPLETED | Follicular Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma |
Polish Lymphoma Research Group |
2007-02 | PHASE3 |
| NCT01145430 | COMPLETED | Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2010-06-01 | PHASE1 |
| NCT01655693 | COMPLETED | Carcinoma, Hepatocellular |
Valerio Therapeutics |
2012-06 | PHASE3 |
| NCT02096588 | TERMINATED | Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-05-20 | PHASE2 |
| NCT01476410 | COMPLETED | Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma |
Northwestern University |
2011-11 | PHASE2 |
| NCT03339804 | COMPLETED | Breast Cancer; Chemotherapeutic Toxicity |
University of Sao Paulo General Hospital |
2016-02-22 | |
| NCT02292979 | COMPLETED | Hodgkin Lymphoma |
The Lymphoma Academic Research Organisation |
2015-03 | PHASE2 |
| NCT01193842 | COMPLETED | AIDS-Related Plasmablastic Lymphoma; AIDS-Related Primary Effusion Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma; Ann Arbor Stage I Grade 3 Follicular Lymphoma; Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma; HIV Infection; Plasmablastic Lymphoma; Primary Effusion Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma |
National Cancer Institute (NCI) |
2010-10-06 | PHASE1; PHASE2 |
| NCT02125344 | COMPLETED | Tubular Breast Cancer Stage II; Tubular Breast Cancer Stage III; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; HER2 Positive Breast Cancer; Inflammatory Breast Cancer |
GBG Forschungs GmbH |
2014-12 | PHASE3 |
| NCT02261805 | TERMINATED | Cancer; Small Cell Lung Cancer |
Georgetown University |
2014-10 | PHASE1; PHASE2 |
| NCT01696032 | COMPLETED | Ovarian Cancer |
Astex Pharmaceuticals, Inc. |
2012-09 | PHASE2 |
| NCT01666444 | COMPLETED | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer |
Celgene |
2012-10-31 | PHASE2 |
| NCT00575952 | COMPLETED | Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Mixed Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Squamous Cell Carcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer |
Gynecologic Oncology Group |
2008-01-17 | PHASE1 |
| NCT02531308 | TERMINATED | Diffuse Large B-Cell Lymphoma |
Rush University Medical Center |
2015-07 | PHASE2 |
| NCT00379340 | COMPLETED | Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor |
Children's Oncology Group |
2007-04-30 | PHASE3 |
| NCT01055314 | COMPLETED | Adult Rhabdomyosarcoma; Childhood Alveolar Rhabdomyosarcoma; Childhood Embryonal Rhabdomyosarcoma; Metastatic Childhood Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Untreated Childhood Rhabdomyosarcoma |
National Cancer Institute (NCI) |
2010-01 | PHASE2 |
| NCT00450385 | TERMINATED | Lymphoma |
University of Miami |
2007-04-24 | PHASE2 |
| NCT00920153 | TERMINATED | Lymphoma |
French Innovative Leukemia Organisation |
2008-05 | PHASE3 |
| NCT00381680 | COMPLETED | B-cell Childhood Acute Lymphoblastic Leukemia; L1 Childhood Acute Lymphoblastic Leukemia; L2 Childhood Acute Lymphoblastic Leukemia; Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia |
Children's Oncology Group |
2007-03 | PHASE3 |
| NCT01332968 | COMPLETED | Non-Hodgkin's Lymphoma |
Hoffmann-La Roche |
2011-07-06 | PHASE3 |
| NCT01132807 | COMPLETED | Lymphoma |
Alliance for Clinical Trials in Oncology |
2010-05 | PHASE2 |
| NCT00678327 | COMPLETED | Lymphoma |
University College, London |
2008-08-29 | PHASE3 |
| NCT02255110 | TERMINATED | Soft Tissue Sarcoma |
Merck KGaA, Darmstadt, Germany |
2014-12-10 | PHASE2 |
| NCT01839097 | COMPLETED | Peripheral T-cell Lymphoma |
Acrotech Biopharma Inc. |
2013-05 | PHASE1 |
| NCT00972478 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage II Non-Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma |
National Cancer Institute (NCI) |
2010-11-15 | PHASE1; PHASE2 |
| NCT00470223 | ACTIVE_NOT_RECRUITING | Sarcoma |
UNICANCER |
2007-03 | PHASE3 |
| NCT01215344 | COMPLETED | Multiple Myeloma |
Vanderbilt-Ingram Cancer Center |
2010-11 | PHASE2 |
| NCT00634179 | COMPLETED | Lymphoma, B-Cell; Follicular Lymphoma |
Emory University |
2008-02 | PHASE1; PHASE2 |
| NCT01100944 | TERMINATED | Thymoma; Thymic Carcinoma |
National Cancer Institute (NCI) |
2010-03-04 | PHASE1; PHASE2 |
| NCT01333423 | WITHDRAWN | Breast Cancer |
M.D. Anderson Cancer Center |
2012-09 | PHASE1 |
| NCT01946529 | COMPLETED | Desmoplastic Small Round Cell Tumor; Ewing Sarcoma of Bone or Soft Tissue; Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
St. Jude Children's Research Hospital |
2013-12-27 | PHASE2 |
| NCT02237690 | COMPLETED | Ovarian Cancer |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
2014-09 | PHASE1 |
| NCT00931918 | COMPLETED | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) |
Millennium Pharmaceuticals, Inc. |
2009-10 | PHASE2 |
| NCT00450801 | COMPLETED | Lymphoma |
University of Miami |
2004-04 | PHASE2 |
| NCT01498588 | TERMINATED | Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of the Breast; Neoplasms, Breast; Tumors, Breast |
Emory University |
2011-11 | PHASE2 |
| NCT00923936 | COMPLETED | Sarcoma, Kaposi |
National Cancer Institute (NCI) |
2009-04-23 | PHASE2 |
| NCT02116530 | COMPLETED | Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific |
Alliance for Clinical Trials in Oncology |
2014-08-20 | PHASE3 |
| NCT00203502 | COMPLETED | Breast Cancer |
University of Arkansas |
2005-09 | PHASE2 |
| NCT00021255 | COMPLETED | Breast Neoplasms |
Sanofi |
2001-04 | PHASE3 |
| NCT01111903 | COMPLETED | Ovarian Cancer Recurrent |
ARCAGY/ GINECO GROUP |
2009-05 | PHASE1; PHASE2 |
| NCT01220128 | TERMINATED | Neoplasms, Breast |
GlaxoSmithKline |
2011-04-11 | PHASE2 |
| NCT01324076 | UNKNOWN | Liver Cancer |
University College, London |
2010-11 | PHASE3 |
| NCT00101010 | COMPLETED | Lymphoma |
M.D. Anderson Cancer Center |
2005-09 | PHASE2 |
| NCT01658358 | TERMINATED | Metastatic Breast Cancer |
China Medical University Hospital |
2012-07 | PHASE1; PHASE2 |
| NCT00861705 | COMPLETED | Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2009-07-21 | PHASE2 |
| NCT00976911 | COMPLETED | Ovarian Cancer |
Hoffmann-La Roche |
2009-10-29 | PHASE3 |
| NCT01313884 | TERMINATED | Bone Cancer; Ewing's Sarcoma |
Stanford University |
2011-05 | PHASE2 |
| NCT00866307 | COMPLETED | Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia |
Children's Oncology Group |
2009-02-23 | PHASE1 |
| NCT01969032 | COMPLETED | Triple Negative Breast Cancer |
Russian Academy of Medical Sciences |
2011-08 | PHASE2 |
| NCT00944047 | COMPLETED | Breast Cancer |
University of Kansas Medical Center |
2009-07 | PHASE2 |
| NCT01514188 | COMPLETED | Metastatic Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma |
ImmunityBio, Inc. |
2012-01-11 | PHASE2 |
| NCT00895414 | COMPLETED | Breast Cancer |
Masonic Cancer Center, University of Minnesota |
2009-04 | |
| NCT01659554 | TERMINATED | Recurrent Ovarian Cancer; Fallopian Tube Cancer |
Columbia University |
2012-03 | PHASE2 |
| NCT00014222 | COMPLETED | Breast Cancer |
NCIC Clinical Trials Group |
2000-12-04 | PHASE3 |
| NCT01415765 | WITHDRAWN | Lymphoma, Diffuse Large-Cell B-cell; Diffuse, Large B-cell Lymphoma; Lymphoma, Diffuse Large-Cell; Large-Cell Lymphoma, Diffuse |
National Cancer Institute (NCI) |
2011-07-15 | PHASE1; PHASE2 |
| NCT00103285 | COMPLETED | Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia |
Children's Oncology Group |
2005-04-11 | PHASE3 |
| NCT00107380 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
2005-11 | PHASE2 |
| NCT00254592 | COMPLETED | Breast Cancer |
University of California, Irvine |
2005-10 | PHASE2 |
| NCT01004991 | COMPLETED | Diffuse Large B Cell Lymphoma |
Weill Medical College of Cornell University |
2010-01 | PHASE1; PHASE2 |
| NCT01328236 | UNKNOWN | Plasma Cell Leukemia; Multiple Myeloma |
Clinical Service, China |
2010-09 | PHASE2 |
| NCT00671658 | COMPLETED | Leukemia; Acute Lymphoblastic Leukemia |
M.D. Anderson Cancer Center |
2002-11 | PHASE2 |
| NCT00002721 | COMPLETED | Prostate Cancer |
University of New Mexico |
1995-03 | PHASE1 |
| NCT01640847 | WITHDRAWN | Painful Bone Metastases; Breast Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Adenocarcinoma |
Imunon |
2012-07 | PHASE2 |
| NCT01605526 | COMPLETED | Sarcoma |
Hoffmann-La Roche |
2012-05 | PHASE1 |
| NCT00949182 | COMPLETED | Liver Cancer |
Rutgers, The State University of New Jersey |
2009-07 | PHASE2 |
| NCT01189253 | TERMINATED | Sarcoma |
European Organisation for Research and Treatment of Cancer - EORTC |
2011-05 | PHASE2; PHASE3 |
| NCT00617591 | COMPLETED | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2008-01 | PHASE2 |
| NCT01415336 | UNKNOWN | Breast Cancer |
Peking Union Medical College Hospital |
2010-03 | PHASE2; PHASE3 |
| NCT01005914 | TERMINATED | Leukemia |
OHSU Knight Cancer Institute |
2009-06 | PHASE2 |
| NCT01095926 | COMPLETED | Wilms Tumor; Neuroblastoma; Soft Tissue Sarcoma; Acute Lymphoblastic Leukemia |
University Hospital Muenster |
2010-05 | PHASE2 |
| NCT01321775 | UNKNOWN | Breast Cancer |
Hospital Universitario Madrid Sanchinarro |
2009-08 | PHASE2 |
| NCT00911183 | COMPLETED | Lymphoma |
Institut Bergonié |
2008-12-02 | PHASE2 |
| NCT00878800 | COMPLETED | Dose Escalation: Solid Tumors; MTD: Soft Tissue Sarcomas |
Valerio Therapeutics |
2006-12 | PHASE1; PHASE2 |
| NCT00976131 | COMPLETED | Breast Cancer |
Columbia University |
2009-09 | PHASE1 |
| NCT00666484 | COMPLETED | Lymphoma; Neurotoxicity |
University College, London |
2008-03 | PHASE2 |
| NCT01040871 | COMPLETED | Diffuse Large B-Cell Lymphoma |
Millennium Pharmaceuticals, Inc. |
2010-01 | PHASE2 |
| NCT00268853 | COMPLETED | Diffuse Large-Cell Lymphoma |
CTI BioPharma |
2005-11 | PHASE2 |
| NCT01259024 | TERMINATED | Hepatocellular Carcinoma |
Washington University School of Medicine |
2011-12 | |
| NCT01181999 | UNKNOWN | Lymphoma, Large B-cell, Diffuse |
Chonnam National University Hospital |
2010-08 | PHASE2 |
| NCT01131364 | TERMINATED | Advanced Solid Tumor; Breast Cancer |
Philogen S.p.A. |
2008-06 | PHASE1; PHASE2 |
| NCT00770536 | COMPLETED | Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors |
Amgen |
2009-01 | PHASE1 |
| NCT00430118 | COMPLETED | Leukemia |
University Hospital Schleswig-Holstein |
2000-07 | PHASE3 |
| NCT00307294 | COMPLETED | Prostate Cancer |
University of Pittsburgh |
2006-03 | PHASE2 |
| NCT00969462 | COMPLETED | Non-Hodgkin's Lymphoma |
Meir Medical Center |
2009-09 | PHASE4 |
| NCT00744354 | TERMINATED | Multiple Myeloma and Plasma Cell Neoplasm |
UNC Lineberger Comprehensive Cancer Center |
2008-10 | PHASE1 |
| NCT00020566 | UNKNOWN | Sarcoma |
University of Leicester |
2001-02 | PHASE3 |
| NCT00544778 | TERMINATED | Sarcoma |
City of Hope Medical Center |
2001-08 | PHASE2 |
| NCT01258634 | TERMINATED | Osteosarcoma; Lung Metastases |
University of Chicago |
2010-07 | PHASE1 |
| NCT01329640 | TERMINATED | Locally Advanced HER2-positive Breast Cancer |
Instituto do Cancer do Estado de São Paulo |
2010-09 | PHASE2 |
| NCT00006721 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
2001-03 | PHASE3 |
| NCT00002766 | COMPLETED | Leukemia; Lymphoma |
Memorial Sloan Kettering Cancer Center |
1996-03 | PHASE3 |
| NCT00785798 | TERMINATED | Relapsed Lymphomas; Refractory Lymphomas |
Yale University |
2009-01 | PHASE1; PHASE2 |
| NCT00861120 | COMPLETED | Epithelial Ovarian Cancer |
Vejle Hospital |
2009-04 | PHASE2 |
| NCT00992706 | COMPLETED | Breast Cancer; Palmar-plantar Erythrodysesthesia |
Swiss Cancer Institute |
2009-09 | PHASE3 |
| NCT00903630 | TERMINATED | Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer |
Masonic Cancer Center, University of Minnesota |
2009-04 | PHASE1; PHASE2 |
| NCT00569257 | COMPLETED | Ovarian Cancer; Endometrial Cancer |
AEterna Zentaris |
2007-12 | PHASE2 |
| NCT01110603 | TERMINATED | Cancer: Solid Tumors |
Tesaro, Inc. |
2010-07 | PHASE1 |
| NCT00703170 | COMPLETED | Resistant Solid Malignancies |
Washington University School of Medicine |
2008-03 | PHASE1 |
| NCT00048893 | TERMINATED | Breast Neoplasms; Metastases, Neoplasm |
National Cancer Institute (NCI) |
2002-11 | PHASE1; PHASE2 |
| NCT00290732 | COMPLETED | Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2005-11 | PHASE1 |
| NCT00003907 | COMPLETED | Liver Cancer; Metastatic Cancer |
Eastern Cooperative Oncology Group |
1999-12-15 | PHASE2 |
| NCT00509665 | COMPLETED | Head and Neck Cancer |
Medical University of South Carolina |
2005-06 | PHASE2 |
| NCT00379457 | UNKNOWN | Sarcoma |
European Paediatric Soft Tissue Sarcoma Study Group |
2006-06 | PHASE3 |
| NCT00877071 | COMPLETED | Hepatocellular Carcinoma |
University of Pittsburgh |
2008-11 | PHASE2 |
| NCT00983944 | WITHDRAWN | Lymphoma |
Ohio State University Comprehensive Cancer Center |
2009-09 | PHASE2 |
| NCT00458705 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Memorial Sloan Kettering Cancer Center |
2006-11 | PHASE2 |
| NCT00256243 | COMPLETED | Breast Cancer |
Rita Sanghvi, Mehta |
2004-04 | PHASE2 |
| NCT00366106 | TERMINATED | Multiple Myeloma |
Accelerated Community Oncology Research Network |
2006-07 | PHASE2 |
| NCT00194753 | COMPLETED | Breast Neoplasm |
University of Washington |
2001-12 | PHASE2 |
| NCT00005047 | TERMINATED | Bladder Cancer |
SWOG Cancer Research Network |
1997-08 | PHASE3 |
| NCT00088881 | TERMINATED | Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Testicular Lymphoma; Waldenström Macroglobulinemia |
National Cancer Institute (NCI) |
2004-12 | PHASE2 |
| NCT00148317 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2005-06 | PHASE2 |
| NCT00671476 | UNKNOWN | Breast Cancer |
Dr. Susan Love Research Foundation |
2008-02 | |
| NCT01051362 | UNKNOWN | Non-small Cell Lung Cancer |
The First Affiliated Hospital of Guangzhou Medical University |
2006-02 | PHASE2 |
| NCT00121992 | COMPLETED | Breast Neoplasms |
Spanish Breast Cancer Research Group |
1999-07 | PHASE3 |
| NCT00524316 | TERMINATED | Liver Cancer |
Roswell Park Cancer Institute |
2007-04 | PHASE2 |
| NCT00475683 | COMPLETED | Chemotherapy Induced Mucositis |
Hadassah Medical Organization |
2009-01 | PHASE3 |
| NCT00673179 | TERMINATED | Osteosarcoma |
M.D. Anderson Cancer Center |
2008-05 | |
| NCT01100359 | UNKNOWN | Endometrial Cancer |
Medical University Innsbruck |
2007-11 | PHASE2 |
| NCT00862836 | TERMINATED | Ovarian Cancer |
Genzyme, a Sanofi Company |
2009-04 | PHASE1; PHASE2 |
| NCT00801580 | UNKNOWN | Lymphoid Leukemia |
University of Bologna |
2008-03 | PHASE2 |
| NCT00550771 | COMPLETED | Breast Neoplasm |
Merck Sharp & Dohme LLC |
2007-07-16 | PHASE2 |
| NCT00742404 | UNKNOWN | Multiple Myeloma and Plasma Cell Neoplasm |
Oncotherapeutics |
2008-07 | PHASE2 |
| NCT00135499 | TERMINATED | Lymphoma, Large-Cell, Diffuse |
Lymphoma Study Association |
2001-10-16 | PHASE3 |
| NCT00006011 | COMPLETED | Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Stage III Uterine Corpus Cancer |
Gynecologic Oncology Group |
2000-07 | PHASE3 |
| NCT00289809 | COMPLETED | Sarcoma, Soft Tissue |
Istituto Clinico Humanitas |
2006-09 | PHASE1; PHASE2 |
| NCT00533936 | UNKNOWN | Breast Cancer |
Instituto Nacional de Cancerologia, Columbia |
2006-09 | PHASE2 |
| NCT00455533 | COMPLETED | Breast Cancer |
Bristol-Myers Squibb |
2007-10 | PHASE2 |
| NCT00071058 | COMPLETED | Adrenal Cortex Neoplasms |
National Cancer Institute (NCI) |
2003-10 | PHASE2 |
| NCT00377559 | COMPLETED | Breast Cancer; Neoplasm Metastasis |
Catharina Ziekenhuis Eindhoven |
2006-05 | PHASE2 |
| NCT00720096 | TERMINATED | Ovarian Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2008-07 | |
| NCT00003135 | UNKNOWN | Breast Cancer; Cervical Cancer; Endometrial Cancer; Ovarian Cancer |
The University of Texas Health Science Center, Houston |
1997-11 | PHASE2 |
| NCT00119262 | COMPLETED | Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer |
National Cancer Institute (NCI) |
2005-10 | PHASE2 |
| NCT00814541 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Cancer Trials Ireland |
2005-12 | PHASE2 |
| NCT00407888 | COMPLETED | Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer |
University of Washington |
2006-05 | PHASE2 |
| NCT00562068 | UNKNOWN | Lymphoma; Small Intestine Cancer |
Cancer Research UK |
2007-05 | PHASE1 |
| NCT00886028 | UNKNOWN | Malignant Pleural Mesothelioma |
National Institute of Cancerología |
2006-09 | PHASE2 |
| NCT00494780 | COMPLETED | Lymphoma, Follicular |
GlaxoSmithKline |
2007-06 | PHASE2 |
| NCT00562185 | WITHDRAWN | Ovarian Cancer |
University of Texas Southwestern Medical Center |
2008-05 | PHASE1; PHASE2 |
| NCT00523380 | COMPLETED | Cancer; Ovarian Cancer |
Novo Nordisk A/S |
2007-10-04 | PHASE2 |
| NCT00426127 | TERMINATED | Pancreatic Cancer |
University of Iowa |
2006-11 | PHASE2 |
| NCT00478374 | COMPLETED | Hepatocellular Carcinoma |
University of Bern |
2007-05 | PHASE1 |
| NCT00189553 | COMPLETED | Ovarian Cancer; Fallopian Tube Cancer |
ARCAGY/ GINECO GROUP |
2005-04 | PHASE3 |
| NCT00193037 | COMPLETED | Breast Cancer |
SCRI Development Innovations, LLC |
2001-02 | PHASE2 |
| NCT00985907 | TERMINATED | Multiple Myeloma; Patient Participation |
University of California, San Francisco |
2004-10-28 | PHASE1; PHASE2 |
| NCT00301821 | COMPLETED | Lymphoma |
Alliance for Clinical Trials in Oncology |
2006-01 | PHASE2 |
| NCT01396655 | COMPLETED | Breast Cancer |
Seoul National University Hospital |
2006-07 | PHASE2 |
| NCT00410462 | UNKNOWN | Ovarian Cancer; Sarcoma; Small Intestine Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2006-10 | PHASE2 |
| NCT00244985 | COMPLETED | Lymphoma |
Roswell Park Cancer Institute |
2005-09 | PHASE1; PHASE2 |
| NCT00093834 | COMPLETED | Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2004-01 | PHASE1 |
| NCT00102973 | COMPLETED | Ovarian Neoplasms |
Telik |
2004-12 | PHASE3 |
| NCT00245050 | COMPLETED | Breast Cancer; Drug/Agent Toxicity by Tissue/Organ; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer |
Case Comprehensive Cancer Center |
2004-04 | PHASE3 |
| NCT00609765 | TERMINATED | Pancreatic Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2007-08 | PHASE2 |
| NCT00365417 | COMPLETED | Breast Cancer |
NSABP Foundation Inc |
2006-08 | PHASE2 |
| NCT00544765 | COMPLETED | Breast Cancer |
GBG Forschungs GmbH |
2002-09 | PHASE3 |
| NCT00005945 | COMPLETED | Leukemia |
Children's Oncology Group |
2000-06 | PHASE3 |
| NCT00041132 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
2002-09 | PHASE2 |
| NCT00004188 | COMPLETED | Neuroblastoma |
Children's Oncology Group |
2001-02 | PHASE3 |
| NCT00780039 | COMPLETED | Ovarian Neoplasms |
Merck Sharp & Dohme LLC |
2003-10-01 | PHASE2 |
| NCT00075634 | COMPLETED | Recurrent Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2003-12 | PHASE1 |
| NCT00093509 | COMPLETED | Sarcoma |
Mark Dewhirst |
1999-11 | PHASE1; PHASE2 |
| NCT00128778 | COMPLETED | Breast Neoplasms |
Spanish Breast Cancer Research Group |
2002-10-28 | PHASE4 |
| NCT00135135 | COMPLETED | Neuroblastoma |
St. Jude Children's Research Hospital |
2005-08 | PHASE2 |
| NCT00261313 | COMPLETED | Breast Cancer |
Amgen |
2005-12 | PHASE2 |
| NCT00561743 | COMPLETED | Multiple Myeloma |
Janssen-Ortho Inc., Canada |
2005-11 | PHASE2 |
| NCT00004125 | COMPLETED | Breast Cancer |
Eastern Cooperative Oncology Group |
1999-11-16 | PHASE3 |
| NCT00146562 | COMPLETED | Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer |
Harold J. Burstein, MD, PhD |
2003-07 | PHASE2 |
| NCT00002542 | COMPLETED | Breast Cancer |
NCIC Clinical Trials Group |
1993-07-20 | PHASE3 |
| NCT00002565 | COMPLETED | Lymphoma |
M.D. Anderson Cancer Center |
1994-05-25 | PHASE3 |
| NCT00176293 | TERMINATED | Prostate Cancer |
University of Kentucky |
2005-10 | PHASE2 |
| NCT00053768 | COMPLETED | Lymphoma |
German High-Grade Non-Hodgkin's Lymphoma Study Group |
2002-04 | PHASE3 |
| NCT00019864 | TERMINATED | Cardiac Toxicity; Sarcoma |
National Cancer Institute (NCI) |
2000-03 | PHASE2 |
| NCT00020943 | COMPLETED | Lymphoma |
Alliance for Clinical Trials in Oncology |
2001-06 | PHASE2 |
| NCT00041327 | COMPLETED | Lymphoma |
AIDS Malignancy Consortium |
2002-10 | PHASE2 |
| NCT00652860 | COMPLETED | Metastatic Cancer; Sarcoma |
Mayo Clinic |
2001-08 | PHASE2 |
| NCT00016406 | COMPLETED | Breast Cancer |
SWOG Cancer Research Network |
2001-05 | PHASE3 |
| NCT00779285 | TERMINATED | Breast Neoplasm |
Merck Sharp & Dohme LLC |
2006-02 | PHASE4 |
| NCT00007904 | COMPLETED | Breast Cancer |
Case Comprehensive Cancer Center |
2000-07 | PHASE2 |
| NCT00054158 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Roswell Park Cancer Institute |
2004-08 | PHASE2 |
| NCT00049569 | COMPLETED | L1 Childhood Acute Lymphoblastic Leukemia; L2 Childhood Acute Lymphoblastic Leukemia; Non-T, Non-B Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia |
National Cancer Institute (NCI) |
2003-01 | |
| NCT00309881 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2003-04 | PHASE2 |
| NCT00006235 | COMPLETED | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Gynecologic Oncology Group |
PHASE1 | |
| NCT00008242 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Memorial Sloan Kettering Cancer Center |
2000-08 | PHASE2 |
| NCT00165191 | COMPLETED | Adenocarcinoma of Stomach; Adenocarcinoma of GE Junction; Adenocarcinoma of Esophagus |
Dana-Farber Cancer Institute |
1998-08 | PHASE2 |
| NCT00005800 | COMPLETED | Breast Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
1999-04 | PHASE2 |
| NCT00023998 | COMPLETED | Metastatic Osteosarcoma |
National Cancer Institute (NCI) |
2001-07 | PHASE2 |
| NCT00039481 | COMPLETED | Cardiac Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2002-11 | PHASE1 |
| NCT00189410 | COMPLETED | Cancer of the Ovary Treated as 2nd Line Therapy; Muellerian Mixed Tumours; Tumours of the Uterus; Cervical Cancers; Non-Epithelial Ovarian Tumours |
AGO Study Group |
2003-06 | PHASE2 |
| NCT00461344 | TERMINATED | Ductal Carcinoma |
Sanofi |
2004-07 | PHASE2 |
| NCT00002855 | COMPLETED | Prostate Cancer |
M.D. Anderson Cancer Center |
1996-08 | PHASE3 |
| NCT00193115 | COMPLETED | Breast Cancer |
SCRI Development Innovations, LLC |
2004-03 | PHASE2 |
| NCT00005090 | TERMINATED | Lymphoma |
SWOG Cancer Research Network |
2000-04 | PHASE3 |
| NCT00002466 | COMPLETED | Kidney Cancer; Sarcoma |
Memorial Sloan Kettering Cancer Center |
1990-05 | PHASE2 |
| NCT00005970 | COMPLETED | Breast Adenocarcinoma; HER2 Positive Breast Carcinoma; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7 |
National Cancer Institute (NCI) |
2000-05-19 | PHASE3 |
| NCT00032019 | COMPLETED | Lymphoma |
Alliance for Clinical Trials in Oncology |
2002-02 | PHASE2 |
| NCT00006825 | COMPLETED | Breast Cancer |
NYU Langone Health |
2000-07 | PHASE1; PHASE2 |
| NCT00003691 | COMPLETED | Endometrial Cancer |
Gynecologic Oncology Group |
1998-12 | PHASE3 |
| NCT00080782 | TERMINATED | Metastatic Cancer; Prostate Cancer |
M.D. Anderson Cancer Center |
2002-02 | PHASE2 |
| NCT00002700 | COMPLETED | Leukemia; Lymphoma |
European Organisation for Research and Treatment of Cancer - EORTC |
1995-08 | PHASE3 |
| NCT00002494 | COMPLETED | Leukemia; Lymphoma |
Alliance for Clinical Trials in Oncology |
1992-05 | PHASE2 |
| NCT00009997 | COMPLETED | Breast Cancer |
NYU Langone Health |
1999-03 | PHASE1 |
| NCT00002657 | COMPLETED | Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm |
SWOG Cancer Research Network |
1995-05 | PHASE2 |
| NCT00023855 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
University of Wisconsin, Madison |
2001-06 | PHASE1 |
| NCT00016341 | TERMINATED | Endometrial Cancer |
Gynecologic Oncology Group |
2001-05 | PHASE3 |
| NCT00004010 | COMPLETED | Lymphoma |
Children's Oncology Group |
1999-10 | PHASE2 |
| NCT00002548 | COMPLETED | Multiple Myeloma |
SWOG Cancer Research Network |
1994-01 | PHASE3 |
| NCT00002878 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Eastern Cooperative Oncology Group |
1997-06-30 | PHASE3 |
| NCT00005991 | COMPLETED | Breast Cancer |
M.D. Anderson Cancer Center |
1997-08-25 | PHASE2 |
| NCT00003038 | COMPLETED | Adrenocortical Carcinoma; Breast Cancer; Colorectal Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
Mayo Clinic |
1997-10 | PHASE1 |
| NCT00005822 | COMPLETED | Breast Cancer |
Case Comprehensive Cancer Center |
2000-04 | PHASE1 |
| NCT00002610 | COMPLETED | Kidney Cancer |
Children's Oncology Group |
1996-01 | PHASE3 |
| NCT00008073 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
University of Pittsburgh |
1996-01 | PHASE1 |
| NCT00016172 | COMPLETED | Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
Memorial Sloan Kettering Cancer Center |
2000-11 | PHASE1 |
| NCT00002665 | COMPLETED | Leukemia; Neutropenia; Thrombocytopenia |
SWOG Cancer Research Network |
1995-07 | PHASE2 |
| NCT00004123 | COMPLETED | Sarcoma |
M.D. Anderson Cancer Center |
1997-07 | PHASE1 |
| NCT00003682 | TERMINATED | Prostate Cancer |
UNICANCER |
1998-10 | PHASE3 |
| NCT00003086 | TERMINATED | Breast Cancer |
Louisiana State University Health Sciences Center Shreveport |
1997-03 | PHASE1; PHASE2 |
| NCT00002764 | COMPLETED | Endometrial Cancer; Kidney Cancer; Metastatic Cancer; Ovarian Cancer; Pheochromocytoma; Sarcoma |
European Organisation for Research and Treatment of Cancer - EORTC |
1996-04 | PHASE3 |
| NCT00002618 | COMPLETED | Lymphoma |
Children's Oncology Group |
1994-12 | PHASE3 |
| NCT00002462 | ACTIVE_NOT_RECRUITING | Lymphoma |
European Organisation for Research and Treatment of Cancer - EORTC |
1989-09 | PHASE3 |
| NCT00003776 | COMPLETED | Sarcoma |
Memorial Sloan Kettering Cancer Center |
1998-12 | PHASE2 |
| NCT00003050 | COMPLETED | Breast Cancer |
University of Southern California |
1997-04 | PHASE2 |
| NCT00006669 | WITHDRAWN | Lymphoma |
Medstar Health Research Institute |
1999-09 | PHASE2 |
| NCT00002993 | TERMINATED | Sarcoma |
Gynecologic Oncology Group |
1997-08 | PHASE2 |
| NCT00004039 | WITHDRAWN | Lymphoma |
Hoag Memorial Hospital Presbyterian |
1998-06 | PHASE2 |
| NCT00379041 | ACTIVE_NOT_RECRUITING | Lymphoma |
European Organisation for Research and Treatment of Cancer - EORTC |
1993-09-01 | PHASE3 |
| NCT00590785 | COMPLETED | High Risk; Breast Cancer; Positive Nodes; Cyclophosphamide; Doxorubicin |
National Cancer Institute (NCI) |
1996-08-13 | PHASE3 |
| NCT00080925 | COMPLETED | Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms |
National Institutes of Health Clinical Center (CC) |
2004-02 | PHASE1 |
| NCT00052351 | COMPLETED | Breast Cancer |
National Cancer Institute (NCI) |
2002-09 | PHASE2 |
| NCT00025623 | COMPLETED | Neuroblastoma |
European Infant Neuroblastoma Study Group - 1999 |
1999-07 | PHASE2 |
| NCT00669812 | UNKNOWN | Lymphoma; Small Intestine Cancer |
Cancer Research UK |
2008-02 | PHASE2 |
| NCT00002531 | UNKNOWN | Leukemia |
Johann Wolfgang Goethe University Hospital |
1993-01 | PHASE2 |
| NCT00434031 | WITHDRAWN | Breast Cancer |
National Cancer Institute, Naples |
2007-09 | PHASE2 |
| NCT00217503 | COMPLETED | Lymphoma |
National Cancer Institute (NCI) |
2005-07 | PHASE2 |
| NCT01490047 | WITHDRAWN | Solid Tumors; Lymphomas |
Ludwig Institute for Cancer Research |
2013-01 | PHASE1 |
| NCT00002987 | UNKNOWN | Lymphoma |
Medical Research Council |
1997-01 | PHASE3 |
| NCT00003679 | UNKNOWN | Breast Cancer |
Scottish Cancer Therapy Network |
1998-11 | PHASE3 |
| NCT00003578 | UNKNOWN | Lymphoma |
Lymphoma Trials Office |
1993-01 | PHASE3 |
| NCT00002653 | UNKNOWN | Multiple Myeloma and Plasma Cell Neoplasm |
Medical Research Council |
1993-09 | PHASE3 |
| NCT00003243 | COMPLETED | Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
1998-01 | PHASE1 |
| NCT00025610 | COMPLETED | Neuroblastoma |
European Infant Neuroblastoma Study Group - 1999 |
1999-07 | PHASE2 |
| NCT00002582 | COMPLETED | Breast Cancer |
Institute of Cancer Research, United Kingdom |
1993-06 | PHASE3 |
| NCT00019630 | COMPLETED | Childhood Soft Tissue Sarcoma; Childhood Liver Cancer; Bone Cancer; Brain Tumor; Kidney Tumor |
National Cancer Institute (NCI) |
1999-07 | PHASE1 |
| NCT00023738 | COMPLETED | Sarcoma |
Radiation Therapy Oncology Group |
2001-08 | PHASE1; PHASE2 |
| NCT00003912 | COMPLETED | Liver Cancer |
Societe Internationale d'Oncologie Pediatrique |
1998-06 | PHASE3 |
| NCT00079027 | UNKNOWN | Liver Cancer |
University Hospital Birmingham |
2004-04 | PHASE3 |
| NCT00201318 | COMPLETED | Non-Hodgkin's Lymphoma |
National Health Research Institutes, Taiwan |
2001-09 | PHASE2 |
| NCT00525642 | UNKNOWN | Breast Neoplasms; Adjuvant; Chemotherapy |
Fudan University |
2003-06 | PHASE2; PHASE3 |
| NCT00028886 | UNKNOWN | Multiple Myeloma and Plasma Cell Neoplasm |
Commissie Voor Klinisch Toegepast Onderzoek |
2001-03 | PHASE3 |
| NCT00070447 | COMPLETED | Lymphoma |
National Cancer Institute (NCI) |
2003-11 | PHASE2 |
| NCT00005024 | UNKNOWN | Unspecified Adult Solid Tumor, Protocol Specific |
Jonsson Comprehensive Cancer Center |
PHASE3 | |
| NCT00002147 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
Sequus Pharmaceuticals |
PHASE3 | |
| NCT00001339 | COMPLETED | Adrenal Cortical Carcinoma |
National Cancer Institute (NCI) |
1993-08 | PHASE2 |
| NCT00002477 | UNKNOWN | Ovarian Cancer |
Medical Research Council |
1991-04 | PHASE3 |
| NCT00003421 | COMPLETED | Lymphoma |
Medical Research Council |
1998-06 | PHASE3 |
| NCT00025649 | COMPLETED | Neuroblastoma |
European Infant Neuroblastoma Study Group - 1999 |
1999-07 | PHASE2 |
| NCT00417053 | UNKNOWN | Neuroblastoma |
Children's Cancer and Leukaemia Group |
PHASE3 | |
| NCT00124956 | WITHDRAWN | Cancer |
Boston Children's Hospital |
2003-06 | PHASE1; PHASE2 |
| NCT00000954 | COMPLETED | Sarcoma, Kaposi; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00025428 | COMPLETED | Neuroblastoma |
Societe Internationale d'Oncologie Pediatrique |
2000-12 | PHASE3 |
| NCT00025441 | COMPLETED | Ovarian Cancer; Sarcoma; Small Intestine Cancer |
Societe Internationale d'Oncologie Pediatrique |
1998-11 | PHASE2 |
| NCT00115414 | COMPLETED | Breast Cancer; Fever; Neutropenia |
Amgen |
PHASE2 | |
| NCT00025064 | UNKNOWN | Lymphoma |
Children's Cancer and Leukaemia Group |
2000-01 | PHASE2 |
| NCT00022945 | COMPLETED | Mantle Cell Lymphoma |
Corixa Corporation |
PHASE2 | |
| NCT00132756 | TERMINATED | Prostate Cancer |
Morton Plant Mease Health Care |
2003-12 | PHASE1; PHASE2 |
| NCT00004236 | UNKNOWN | Esophageal Cancer; Gastric Cancer |
University of Leicester |
1998-08 | PHASE2 |
| NCT00024271 | UNKNOWN | Malignant Mesothelioma |
Herbert Irving Comprehensive Cancer Center |
2001-05 | PHASE2 |
| NCT00031187 | COMPLETED | Prostatic Neoplasms |
Seagen Inc. |
2000-10 | PHASE2 |
| NCT00102609 | COMPLETED | Soft Tissue Sarcoma; Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2005-04 | PHASE1 |
| NCT00003296 | UNKNOWN | Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer |
Brown University |
1998-01 | PHASE2 |
| NCT00005959 | UNKNOWN | Lymphoma |
Amgen |
1999-12 | PHASE2 |
| NCT00018954 | COMPLETED | Leukemia; Lymphoma |
National Institutes of Health Clinical Center (CC) |
1992-10 | PHASE2 |
| NCT00536393 | COMPLETED | Lymphoma |
French Innovative Leukemia Organisation |
2000-10 | PHASE2; PHASE3 |
| NCT00344422 | COMPLETED | Multiple Myeloma; Myeloma; M-Protein; Myeloma Proteins |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2000-10 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-06-11)
Check the
Doxorubicin
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.